- Home
- KTTA vs CPHI Comparison
KTTA vs CPHI Comparison
Compare KTTA & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- CPHI
- Stock Information
- Founded
- KTTA 2020
- CPHI N/A
- Country
- KTTA United States
- CPHI China
- Employees
- KTTA N/A
- CPHI N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- CPHI Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- CPHI Health Care
- Exchange
- KTTA Nasdaq
- CPHI Nasdaq
- Market Cap
- KTTA 5.7M
- CPHI 5.8M
- IPO Year
- KTTA 2021
- CPHI N/A
- Fundamental
- Price
- KTTA $0.81
- CPHI $1.64
- Analyst Decision
- KTTA
- CPHI
- Analyst Count
- KTTA 0
- CPHI 0
- Target Price
- KTTA N/A
- CPHI N/A
- AVG Volume (30 Days)
- KTTA 99.4K
- CPHI 11.3K
- Earning Date
- KTTA 11-14-2025
- CPHI 11-13-2025
- Dividend Yield
- KTTA N/A
- CPHI N/A
- EPS Growth
- KTTA N/A
- CPHI N/A
- EPS
- KTTA N/A
- CPHI N/A
- Revenue
- KTTA N/A
- CPHI $4,396,201.00
- Revenue This Year
- KTTA N/A
- CPHI N/A
- Revenue Next Year
- KTTA N/A
- CPHI N/A
- P/E Ratio
- KTTA N/A
- CPHI N/A
- Revenue Growth
- KTTA N/A
- CPHI N/A
- 52 Week Low
- KTTA $0.65
- CPHI $1.20
- 52 Week High
- KTTA $4.35
- CPHI $3.35
- Technical
- Relative Strength Index (RSI)
- KTTA 58.89
- CPHI 37.16
- Support Level
- KTTA $0.71
- CPHI $1.64
- Resistance Level
- KTTA $0.84
- CPHI $1.85
- Average True Range (ATR)
- KTTA 0.05
- CPHI 0.08
- MACD
- KTTA 0.01
- CPHI -0.02
- Stochastic Oscillator
- KTTA 82.47
- CPHI 0.00
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.